Umbralisib (UKONIQ, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, has been approved for relapsed or refractory marginal zone lymphoma and follicular lymphoma.
The white paper provides a summary of the workshop proceedings, presents the key findings of each speaker, and highlights the unmet needs identified during the post-workshop discussion with suggested immediate and long-term solutions.
LRF Urges CDC to Prioritize Blood Cancer Patients for COVID-19 Vaccine VISIT THE COVID-19 LEARNING CENTER FOR MORE UPDATES AND HELPFUL RESOURCES The well-being of the lymphoma community is the top priority of the Lymphoma Research Foundation (LRF). People with cancer, who…
Ask the Doctor: Should CLL patients receive the COVID vaccine while they are on treatment with BTK inhibitors considering that they have to stay on them indefinitely? As of January 2021, there are two COVID-19 vaccines that have been approved…
Peripheral T-cell lymphoma (PTCL) is an aggressive (fast-growing) form of non-Hodgkin lymphoma which has typically been associated with having no standard of care. For most subtypes of PTCL, the initial treatment is typically a combination chemotherapy regimen, such as CHOP…
U.S. Food and Drug Administration (FDA) approved the first biomarker-driven therapy for pediatric ALCL.
Checkpoint inhibitors are a new class of drugs used by the immune system to determine whether or not to launch an immune response. By activating these checkpoints, cancers evade detection by the immune system as something that is bad for…
A lymphoma diagnosis can be challenging to cope with at any time, but the current pandemic has only increased stress, anxiety, and depression for many lymphoma patients. While at times this can all be overwhelming, there are many ways to…
The emergence of biomarking testing has provided new insights into the molecular and genetic underpinnings of many types of cancer as well as differences in an individual patient’s cancer at the molecular level. These differences, or alterations (also known as…
On December 11 and 18, 2020 the U.S. Food and Drug Administration (FDA) issued two COVID-19 vaccines, Pfzier BioNTech and Moderna, with emergency use authorization (EUA). LRF Scientific Advisory Board Member, John Leonard, MD (NewYork-Presbyterian Hospital, Weill Cornell Medicine) answered…
